|Systematic (IUPAC) name|
|Mol. mass||242.3179 g/mol|
|(what is this?)|
JNJ-26990990 is a broad-spectrum anticonvulsant drug currently under development by Janssen Pharmaceutica as a second-generation followup to the marketed drug topiramate. It was designed to have the same anticonvulsant effects as topirimate, but without the side effects associated with topiramate's carbonic anhydrase inhibition. It also has potential use in the treatment of inflammatory pain, neuropathic pain, and depression.
- Michael H. Parker et al. (2009). "Novel, Broad-Spectrum Anticonvulsants Containing a Sulfamide Group: Advancement of N-((Benzo[b]thien-3-yl)methyl)sulfamide (JNJ-26990990) into Human Clinical Studies". Journal of Medicinal Chemistry 52 (23): 7528–36. doi:10.1021/jm801432r. PMID 19388676.
- WO patent 2006023861, Parker, Michael H.; Reitz, Allen B.; Maryanoff, Bruce E., "Preparation of benzo-fused heteroaryl sulfamide derivatives for the treatment of epilepsy and related disorders", issued 2006-03-02, assigned to Janssen Pharmaceutica
- "JNJ 26990990 Johnson & Johnson developing anticonvulsant Johnson & Johnson preclinical data". R & D Focus Drug News. September 22, 2008.
- János Fischer and C. Robin Ganellin (2010). "Chapter 2. Standalone Drugs". Analogue-Based Drug Discovery II. doi:10.1002/9783527630035.ch2.
- Lin, Ronghui; Weaner, Larry E.; Hoerr, David C.; Salter, Rhys; Gong, Yong (2013). "Expeditious syntheses of stable and radioactive isotope-labeled anticonvulsant agent, JNJ-26990990, and its metabolites". Journal of Labelled Compounds and Radiopharmaceuticals 56: 22. doi:10.1002/jlcr.3013.